00-0000000 false 0001808158 0001808158 2024-06-17 2024-06-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2024

 

 

Repare Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Québec   001-39335   Not applicable
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (I.R.S. Employer
Identification No.)

 

7171 Frederick-Banting, Building 2, Suite 270

St-Laurent, Québec, Canada

  H4S 1Z9
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 412-7018

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol

 

Name of each exchange

on which registered

Common shares, no par value   RPTX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 17, 2024, Repare Therapeutics Inc., a corporation governed by the Business Corporations Act (Québec) (the “Company”), held its 2024 Annual Meeting of Shareholders (“Annual Meeting”), at which a quorum was present. At the Annual Meeting, the Company’s shareholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024 (the “Proxy Statement”).

Proposal 1 - Election of Directors

Susan M. Molineaux, Ph.D. and Ann D. Rhoads were each elected to serve as a Class I director of the Company’s Board of Directors (the “Board”) until the 2027 Annual Meeting of Shareholders and until her successor is duly elected or until her earlier death, resignation or removal. The votes cast were as follows:

 

Nominee

   Votes For    Votes Withheld    Broker Non-Votes

Susan M. Molineaux, Ph.D.

   32,268,618    14,009    3,714,807

Ann D. Rhoads

   31,692,160    590,467    3,714,807

Proposal 2 -Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers

The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, by the following votes:

 

Votes For

 

Votes Against

 

Broker Non-Votes

32,257,365   25,262   3,714,807

Proposal 3 - Appointment of Independent Registered Public Accounting Firm

The shareholders approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, and authorized the Board to fix Ernst & Young LLP’s remuneration, by the following votes:

 

Votes For

 

Votes Withheld

35,992,711   4,723


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

REPARE THERAPEUTICS INC.
By:  

/s/ Lloyd M. Segal

  Lloyd M. Segal
  President and Chief Executive Officer

Dated: June 17, 2024

v3.24.1.1.u2
Document and Entity Information
Jun. 17, 2024
Cover [Abstract]  
Entity Incorporation State Country Code A8
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001808158
Document Type 8-K
Document Period End Date Jun. 17, 2024
Entity Registrant Name Repare Therapeutics Inc.
Entity File Number 001-39335
Entity Address, Address Line One 7171 Frederick-Banting, Building 2
Entity Address, Address Line Two Suite 270
Entity Address, City or Town St-Laurent
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4S 1Z9
City Area Code 857
Local Phone Number 412-7018
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common shares, no par value
Trading Symbol RPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Repare Therapeutics (NASDAQ:RPTX)
過去 株価チャート
から 5 2024 まで 6 2024 Repare Therapeuticsのチャートをもっと見るにはこちらをクリック
Repare Therapeutics (NASDAQ:RPTX)
過去 株価チャート
から 6 2023 まで 6 2024 Repare Therapeuticsのチャートをもっと見るにはこちらをクリック